Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Acura Pharmaceuticals's accounts receivables for the quarter that ended in Dec. 2021 was $0.16 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Acura Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2021 was 400.49.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Acura Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2021 was $-0.01.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Acura Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2021 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Acura Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:
Acura Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2021 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Acura Pharmaceuticals Accounts Receivable Related Terms
Acura Pharmaceuticals Accounts Receivable Historical Data
* Premium members only.
The historical data trend for Acura Pharmaceuticals's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of $0.16 Mil mean?
Acura Pharmaceuticals (ACUR) has a Accounts Receivable of $0.16 Mil as of Dec. 2021. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Acura Pharmaceuticals and its competitors.
Is Acura Pharmaceuticals' Accounts Receivable too high?
Acura Pharmaceuticals' current Accounts Receivable is $0.16 Mil. Overall, Acura Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Acura Pharmaceuticals' Accounts Receivable compare to VFRM and THCT?
Acura Pharmaceuticals' Accounts Receivable of $0.16 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Drug Manufacturers company?
A good Accounts Receivable depends on the Drug Manufacturers industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Acura Pharmaceuticals and its competitors. Acura Pharmaceuticals's current Accounts Receivable is $0.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acura Pharmaceuticals stock overvalued right now?
Acura Pharmaceuticals (ACUR) has a current Accounts Receivable of $0.16 Mil. The current Accounts Receivable is $0.16 Mil. Acura Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Acura Pharmaceuticals (ACUR), the current Accounts Receivable is $0.16 Mil as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acura Pharmaceuticals Inc is a drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. It has discovered and developed three proprietary platform technologies which can be used to develop multiple products. Its Limitx Technology is being developed to minimize the risk of overdose, its Aversion Technology is intended to address methods of abuse associated with opioid analgesics while its Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. It operates in single segment being the research, development and commercialization of technologies and products intended to address safe use of medications.
16GF Score
Get the complete analysis for ACUR
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACUR has been successfully added to your 
